Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP) Director Tracy Marshbanks sold 1,381 shares of the stock on the open market in a transaction dated Thursday, May 8th. The stock was sold at an average price of $30.02, for a total value of $41,457.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

ANIP has been the subject of a number of recent research reports. Analysts at Roth Capital raised their price target on shares of ANI Pharmaceuticals from $36.00 to $38.00 in a research note on Tuesday, May 6th. Separately, analysts at Zacks downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 22nd. They now have a $31.60 price target on the stock. Finally, analysts at Zacks upgraded shares of ANI Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Tuesday, March 11th. They now have a $38.50 price target on the stock.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 0.62% during mid-day trading on Monday, hitting $30.55. 72,664 shares of the company’s stock traded hands. ANI Pharmaceuticals has a 52-week low of $4.80 and a 52-week high of $38.74. The stock has a 50-day moving average of $29.82 and a 200-day moving average of $22.58. The company has a market cap of $294.5 million and a price-to-earnings ratio of 221.15.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Monday, May 5th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.32 by $0.01. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The company’s quarterly revenue was up 94.6% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post $1.74 earnings per share for the current fiscal year.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.